Search results for "glucagon-like peptide-1 receptor agonists"

showing 3 items of 3 documents

Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registr…

2022

Abstract Aims Type 2 diabetes (T2DM) in patients with coronavirus disease-19 (COVID-19) is associated with a worse prognosis. We separately investigated the associations between the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and dipeptidyl peptidase-4 inhibitors (DPP-4i), and the risk of COVID-19 hospitalization and death. Methods and results Patients with T2DM registered in the Swedish National Patient Registry and alive on 1 February 2020 were included. ‘Incident severe COVID-19’ was defined as the first hospitalization and/or death from COVID-19. A modified Poisson regression approach was applied to a 1:1 propensity sc…

HospitalizationDipeptidyl-Peptidase IV InhibitorsGlucoseDiabetes Mellitus Type 2Glucagon-Like Peptide 1COVID-19 Dipeptidyl peptidase-4 inhibitors (DPP-4i) Glucagon-like peptide-1 receptor agonists Hospitalization Mortality Sodium-glucose cotransporter 2 inhibitorsHumansCOVID-19Pharmacology (medical)RegistriesCardiology and Cardiovascular MedicineGlucagon-Like Peptide-1 Receptor
researchProduct

Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Trea…

2022

The obesity pandemic is accompanied by increased risk of developing metabolic syndrome (MetS) and related conditions: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease (CVD). Lifestyle, as well as an imbalance of energy intake/expenditure, genetic predisposition, and epigenetics could lead to a dysmetabolic milieu, which is the cornerstone for the development of cardiometabolic complications. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs promote positive effects on most components of the “ cardiometabolic continuum” an…

Metabolic SyndromePharmacologyglucagon-like peptide-1 receptor agonists glucose-dependent insulinotropic polypeptide receptor agonists non-alcoholic fatty liver disease obesity prediabetes tirzepatide type 2 diabetes mellitusGlucagon-Like Peptide-1 ReceptorPrediabetic StateGlucoseDiabetes Mellitus Type 2Non-alcoholic Fatty Liver DiseaseGlucagon-Like Peptide 1HumansPharmacology (medical)ObesityPeptidesCardiology and Cardiovascular MedicineJournal of Cardiovascular Pharmacology and Therapeutics
researchProduct

Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents.

2021

Epidemiological data have demonstrated a significant association between the presence of type 2 diabetes mellitus (T2DM) and the development of colorectal cancer (CRC). Chronic hyperglycemia, insulin resistance, oxidative stress, and inflammation, the processes inherent to T2DM, also play active roles in the onset and progression of CRC. Recently, small dense low-density lipoprotein (LDL) particles, a typical characteristic of diabetic dyslipidemia, emerged as another possible underlying link between T2DM and CRC. Growing evidence suggests that antidiabetic medications may have beneficial effects in CRC prevention. According to findings from a limited number of preclinical and clinical stud…

Oncologyendocrine system diseasesColorectal cancerComorbidityReview0302 clinical medicineinsulin resistanceEpidemiologyBiology (General)small dense LDLSpectroscopyglucagon-like peptide-1 receptor agonists0303 health sciencesIncidenceGeneral MedicineSmall dense LDL3. Good healthComputer Science ApplicationsLipoproteins LDLChemistry030220 oncology & carcinogenesismedicine.symptomColorectal Neoplasmsmedicine.medical_specialtyQH301-705.5InflammationCatalysisGlucagon-like peptide-1 receptor agonistsGlucagon-Like Peptide-1 ReceptorInorganic Chemistry03 medical and health sciencesInsulin resistanceInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsIn patientPhysical and Theoretical ChemistryQD1-999Molecular BiologyAntidiabetic agents030304 developmental biologyInflammationbusiness.industryOrganic ChemistryType 2 Diabetes Mellitusnutritional and metabolic diseasesInsulin resistanceGlucagon-like peptide-1 receptor agonists Hyperglycemia Inflammation Insulin resistance Comorbidity Diabetes Mellitus Type 2 Glucagon-Like Peptide-1 Receptor Humans Hyperglycemia Hypoglycemic Agents Incidence Lipoproteins LDL Oxidative Stress Colorectal Neoplasms Small dense LDLmedicine.diseasedigestive system diseasesOxidative StressDiabetes Mellitus Type 2Oxidative stressinflammationHyperglycemiabusinessInternational journal of molecular sciences
researchProduct